Cargando…

Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge

African swine fever (ASF) is a contagious viral disease of suids that induces high mortality in domestic pigs and wild boars. Given the current spread of ASF, the development of a vaccine is a priority. During an attempt to inactivate the Georgia 2007/1 strain via heat treatment, we fortuitously gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourry, Olivier, Hutet, Evelyne, Le Dimna, Mireille, Lucas, Pierrick, Blanchard, Yannick, Chastagner, Amélie, Paboeuf, Frédéric, Le Potier, Marie-Frédérique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784117/
https://www.ncbi.nlm.nih.gov/pubmed/36560781
http://dx.doi.org/10.3390/v14122777
_version_ 1784857733945622528
author Bourry, Olivier
Hutet, Evelyne
Le Dimna, Mireille
Lucas, Pierrick
Blanchard, Yannick
Chastagner, Amélie
Paboeuf, Frédéric
Le Potier, Marie-Frédérique
author_facet Bourry, Olivier
Hutet, Evelyne
Le Dimna, Mireille
Lucas, Pierrick
Blanchard, Yannick
Chastagner, Amélie
Paboeuf, Frédéric
Le Potier, Marie-Frédérique
author_sort Bourry, Olivier
collection PubMed
description African swine fever (ASF) is a contagious viral disease of suids that induces high mortality in domestic pigs and wild boars. Given the current spread of ASF, the development of a vaccine is a priority. During an attempt to inactivate the Georgia 2007/1 strain via heat treatment, we fortuitously generated an attenuated strain called ASFV-989. Compared to Georgia, the ASFV-989 strain genome has a deletion of 7458 nucleotides located in the 5′-end encoding region of MGF 505/360, which allowed for developing a DIVA PCR system. In vitro, in porcine alveolar macrophages, the replication kinetics of the ASFV-989 and Georgia strains were identical. In vivo, specific-pathogen-free (SPF) pigs inoculated with the ASFV-989 strain, either intramuscularly or oronasally, exhibited transient hyperthermia and slightly decreased growth performance. Animals immunized with the ASFV-989 strain showed viremia 100 to 1000 times lower than those inoculated with the Georgia strain and developed a rapid antibody and cell-mediated response. In ASFV-989-immunized pigs challenged 2 or 4 weeks later with the Georgia strain, no symptoms were recorded and no viremia for the challenge strain was detected. These results show that the ASFV-989 strain is a promising non-GMO vaccine candidate that is usable either intramuscularly or oronasally.
format Online
Article
Text
id pubmed-9784117
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97841172022-12-24 Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge Bourry, Olivier Hutet, Evelyne Le Dimna, Mireille Lucas, Pierrick Blanchard, Yannick Chastagner, Amélie Paboeuf, Frédéric Le Potier, Marie-Frédérique Viruses Article African swine fever (ASF) is a contagious viral disease of suids that induces high mortality in domestic pigs and wild boars. Given the current spread of ASF, the development of a vaccine is a priority. During an attempt to inactivate the Georgia 2007/1 strain via heat treatment, we fortuitously generated an attenuated strain called ASFV-989. Compared to Georgia, the ASFV-989 strain genome has a deletion of 7458 nucleotides located in the 5′-end encoding region of MGF 505/360, which allowed for developing a DIVA PCR system. In vitro, in porcine alveolar macrophages, the replication kinetics of the ASFV-989 and Georgia strains were identical. In vivo, specific-pathogen-free (SPF) pigs inoculated with the ASFV-989 strain, either intramuscularly or oronasally, exhibited transient hyperthermia and slightly decreased growth performance. Animals immunized with the ASFV-989 strain showed viremia 100 to 1000 times lower than those inoculated with the Georgia strain and developed a rapid antibody and cell-mediated response. In ASFV-989-immunized pigs challenged 2 or 4 weeks later with the Georgia strain, no symptoms were recorded and no viremia for the challenge strain was detected. These results show that the ASFV-989 strain is a promising non-GMO vaccine candidate that is usable either intramuscularly or oronasally. MDPI 2022-12-13 /pmc/articles/PMC9784117/ /pubmed/36560781 http://dx.doi.org/10.3390/v14122777 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bourry, Olivier
Hutet, Evelyne
Le Dimna, Mireille
Lucas, Pierrick
Blanchard, Yannick
Chastagner, Amélie
Paboeuf, Frédéric
Le Potier, Marie-Frédérique
Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge
title Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge
title_full Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge
title_fullStr Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge
title_full_unstemmed Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge
title_short Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge
title_sort oronasal or intramuscular immunization with a thermo-attenuated asfv strain provides full clinical protection against georgia 2007/1 challenge
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784117/
https://www.ncbi.nlm.nih.gov/pubmed/36560781
http://dx.doi.org/10.3390/v14122777
work_keys_str_mv AT bourryolivier oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge
AT hutetevelyne oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge
AT ledimnamireille oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge
AT lucaspierrick oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge
AT blanchardyannick oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge
AT chastagneramelie oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge
AT paboeuffrederic oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge
AT lepotiermariefrederique oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge